This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.08.033v1 48/12/2432    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Park, D.-W. Articles by Park, S.-J. Search for Related Content PubMed PubMed Citation Articles by Park, D.-W. Articles by Park, S.-J.

CLINICAL RESEARCH

Two-Year Follow-Up of the Quantitative Angiographic and Volumetric Intravascular Ultrasound Analysis After Nonpolymeric Paclitaxel-Eluting Stent Implantation

Late "Catch-Up" Phenomenon From ASPECT Study

Duk-Woo Park, MD^_*, Myeong-Ki Hong, MD^_*, Gary S. Mintz, MD, FACC, Cheol Whan Lee, MD^_*, Jong-Min Song, MD^_*, Ki-Hoon Han, MD^_*, Duk-Hyun Kang, MD^_*, Sang-Sig Cheong, MD, Jae-Kwan Song, MD, FACC^_*, Jae-Joong Kim, MD^_*, Neil J. Weissman, MD, FACC, Seong-Wook Park, MD, FACC^_* and Seung-Jung Park, MD, FACC^_*,_*

^_* Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul
GangNeung, Korea
Cardiovascular Research Foundation, New York, New York
Washington Hospital Center, Washington, DC

Manuscript received April 14, 2006; revised manuscript received August 1, 2006, accepted August 7, 2006.

^_* Reprint requests and correspondence: Dr. Seung-Jung Park, Departments of Medicine, University of Ulsan College of Medicine, Cardiac Center, Asan Medical Center, 388-1 Poongnap-dong, Songpa-gu, Seoul 138-736, Korea. (Email: sjpark{at}amc.seoul.kr).

OBJECTIVES: This study used serial angiographic and intravascular ultrasound (IVUS) analysis to evaluate the long-term efficacy of a nonpolymeric, paclitaxel-eluting stent coating on intimal hyperplasia (IH) 2 years after implantation.

BACKGROUND: Long-term efficacy of patients treated with nonpolymeric paclitaxel-eluting stents beyond 1 year has not been well determined.

METHODS: Patients were randomized to placebo or 1 of 2 doses of paclitaxel (low dose, 1.28 µg/mm²; high dose, 3.10 µg/mm²). Complete after-procedure, 6-month, and 2-year angiographic and IVUS data were available in 53 patients (17, 17, and 19 patients, respectively).

RESULTS: Baseline characteristics were similar among the 3 groups. Although 6-month minimal luminal diameter (MLD) was significantly smaller in placebo compared with paclitaxel-eluting stent patients (1.9 ± 0.6 mm in placebo, 2.5 ± 0.6 mm in low-dose, and 2.6 ± 0.5 mm in high-dose patients, p = 0.004), the MLDs at 2 years were similar (2.3 ± 0.6 mm, 2.3 ± 0.7 mm, and 2.0 ± 0.8 mm, respectively, p = 0.4). Despite a stepwise reduction in IH accumulation at 6 months (23 ± 18 mm³ in placebo, 14 ± 11 mm³ in low-dose, and 10 ± 12 mm³ in high-dose, p = 0.017), the increase of IH volume from 6 months to 2 years was significantly greater in the high-dose patients (13 ± 14 mm³ in high-dose vs. 4 ± 7 mm³ in low-dose patients, p = 0.074; and vs. 1 ± 13 mm³ in placebo, p = 0.019). Late target lesion revascularization (beyond 1 year) was performed in 2 high-dose patients.

CONCLUSIONS: Despite the suppression of IH after non-polymeric paclitaxel-eluting stents compared with bare-metal stents at 6 months, a "late catch-up" IH growth was found in the high-dose patients at 2-year follow-up.

Abbreviations and Acronyms   BMS = bare-metal stents   DES = drug-eluting stents   IH = intimal hyperplasia   IVUS = intravascular ultrasound   MLA = minimum lumen area   MLD = minimal luminal diameter   QCA = quantitative coronary angiography

This article has been cited by other articles:

				J. D. Douketis, A. C. Spyropoulos, F. A. Spencer, M. Mayr, A. K. Jaffer, M. H. Eckman, A. S. Dunn, and R. Kunz Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest, February 1, 2012; 141(2_suppl): e326S - e350S. [Abstract] [Full Text] [PDF]

				C. A. Collet, J. R. Costa, A. Abizaid, D. Chamie, R. Staico, R. Costa, D. Siquera, J. Obregon, F. Feres, A. Sousa, et al. Assessing the Temporal Course of Neointimal Hyperplasia Formation After Different Generations of Drug-Eluting Stents J. Am. Coll. Cardiol. Intv., October 1, 2011; 4(10): 1067 - 1074. [Abstract] [Full Text] [PDF]

				S.-J. Kang, G. S. Mintz, D.-W. Park, S.-W. Lee, Y.-H. Kim, C. W. Lee, K.-H. Han, J.-J. Kim, S.-W. Park, and S.-J. Park Comparison of Zotarolimus-Eluting Stents With Sirolimus-Eluting and Paclitaxel-Eluting Stents: Intimal Hyperplasia and Vascular Changes Assessed by Volumetric Intravascular Ultrasound Analysis Circ Cardiovasc Interv, April 1, 2011; 4(2): 139 - 145. [Abstract] [Full Text] [PDF]

				S.-J. Kang, G. S. Mintz, D.-W. Park, S.-W. Lee, Y.-H. Kim, C. Whan Lee, K.-H. Han, J.-J. Kim, S.-W. Park, and S.-J. Park Mechanisms of In-Stent Restenosis After Drug-Eluting Stent Implantation: Intravascular Ultrasound Analysis Circ Cardiovasc Interv, February 1, 2011; 4(1): 9 - 14. [Abstract] [Full Text] [PDF]

				N. Kuriyama, Y. Kobayashi, T. Nakama, D. Mine, K. Nishihira, M. Shimomura, K. Nomura, K. Ashikaga, A. Matsuyama, and Y. Shibata Late Restenosis Following Sirolimus-Eluting Stent Implantation J. Am. Coll. Cardiol. Intv., January 1, 2011; 4(1): 123 - 128. [Abstract] [Full Text] [PDF]

				G. Niccoli, R. A. Montone, G. Ferrante, and F. Crea The Evolving Role of Inflammatory Biomarkers in Risk Assessment After Stent Implantation J. Am. Coll. Cardiol., November 23, 2010; 56(22): 1783 - 1793. [Abstract] [Full Text] [PDF]

				M. A. M. Beijk, M. Klomp, N. J. W. Verouden, N. van Geloven, K. T. Koch, J. P. S. Henriques, J. Baan, M. M. Vis, E. Scheunhage, J. J. Piek, et al. GenousTM endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study Eur. Heart J., May 1, 2010; 31(9): 1055 - 1064. [Abstract] [Full Text] [PDF]

				N. Tada, R. Virmani, G. Grant, L. Bartlett, A. Black, C. Clavijo, U. Christians, R. Betts, D. Savage, S. H. Su, et al. Polymer-Free Biolimus A9-Coated Stent Demonstrates More Sustained Intimal Inhibition, Improved Healing, and Reduced Inflammation Compared With a Polymer-Coated Sirolimus-Eluting Cypher Stent in a Porcine Model Circ Cardiovasc Interv, April 1, 2010; 3(2): 174 - 183. [Abstract] [Full Text] [PDF]

				E. Grube, J. Schofer, K. E. Hauptmann, G. Nickenig, N. Curzen, D. J. Allocco, and K. D. Dawkins A Novel Paclitaxel-Eluting Stent With an Ultrathin Abluminal Biodegradable Polymer: 9-Month Outcomes With the JACTAX HD Stent J. Am. Coll. Cardiol. Intv., April 1, 2010; 3(4): 431 - 438. [Abstract] [Full Text] [PDF]

				B. R. Brodie, H. Wilson, T. Stuckey, M. Nussbaum, S. Laurent, B. Bradshaw, A. Humphrey, C. Metzger, J. Hermiller, F. Krainin, et al. Outcomes With Drug-Eluting Versus Bare-Metal Stents in Saphenous Vein Graft Intervention: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group J. Am. Coll. Cardiol. Intv., November 1, 2009; 2(11): 1105 - 1112. [Abstract] [Full Text] [PDF]

				S. Silber, A. Colombo, A. P. Banning, K. Hauptmann, J. Drzewiecki, E. Grube, D. Dudek, and D. S. Baim Final 5-Year Results of the TAXUS II Trial: A Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for De Novo Coronary Artery Lesions Circulation, October 13, 2009; 120(15): 1498 - 1504. [Abstract] [Full Text] [PDF]

				F. Innocente, D. Mandracchia, E. Pektok, B. Nottelet, J.-C. Tille, S. de Valence, G. Faggian, A. Mazzucco, A. Kalangos, R. Gurny, et al. Paclitaxel-Eluting Biodegradable Synthetic Vascular Prostheses: A Step Towards Reduction of Neointima Formation? Circulation, September 15, 2009; 120(11_suppl_1): S37 - S45. [Abstract] [Full Text] [PDF]

				R. A. Byrne, R. Iijima, J. Mehilli, S. Pinieck, O. Bruskina, A. Schomig, and A. Kastrati Durability of Antirestenotic Efficacy in Drug-Eluting Stents With and Without Permanent Polymer J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 291 - 299. [Abstract] [Full Text] [PDF]

				A. V. Finn, G. Nakazawa, F. D. Kolodgie, and R. Virmani Temporal Course of Neointimal Formation After Drug-Eluting Stent Placement: Is Our Understanding of Restenosis Changing? J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 300 - 302. [Full Text] [PDF]

				H. Doi, A. Maehara, G. S. Mintz, N. J. Weissman, A. Yu, H. Wang, L. Mandinov, J. J. Popma, S. G. Ellis, E. Grube, et al. Impact of In-Stent Minimal Lumen Area at 9 Months Poststent Implantation on 3-Year Target Lesion Revascularization-Free Survival: A Serial Intravascular Ultrasound Analysis From the TAXUS IV, V, and VI Trials Circ Cardiovasc Interv, October 1, 2008; 1(2): 111 - 118. [Abstract] [Full Text] [PDF]

				R. Wessely, A. Kastrati, J. Mehilli, A. Dibra, J. Pache, and A. Schomig Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design Eur. Heart J., November 2, 2007; 28(22): 2720 - 2725. [Abstract] [Full Text] [PDF]

				T. Adriaenssens, J. Mehilli, R. Wessely, G. Ndrepepa, M. Seyfarth, A. Wieczorek, B. Blaich, R. Iijima, J. Pache, A. Kastrati, et al. Does Addition of Estradiol Improve the Efficacy of a Rapamycin-Eluting Stent?: Results of the ISAR-PEACE Randomized Trial J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1265 - 1271. [Abstract] [Full Text] [PDF]